Pharmacokinetic Evaluation of Alendronic Acid Oral Formulations in Healthy Volunteers Under Fasted Conditions: A Randomized, Open-Label, Crossover Study

The primary objective of this study is to evaluate the **pharmacokinetics** of alendronic acid oral formulations following a single-dose administration in healthy volunteers under fasted conditions. This investigation is clinically relevant as it provides critical insights into the absorption, distribution, metabolism, and excretion of alendronic acid, which is essential for optimizing dosing regimens and ensuring therapeutic efficacy while minimizing potential adverse effects. No secondary objectives are specified for this study.

The clinical trial involves a **pharmacokinetic study** conducted in **healthy volunteers** under fasted conditions. The study population includes both male and female participants, with an age range category code of 3, which typically corresponds to adults. The trial does not specify the total number of participants, as the sponsor has not provided this information. Participants were selected based on their general health status, ensuring they are healthy individuals. The trial population includes a vulnerable population, although specific details regarding this aspect are not disclosed. Lifestyle considerations such as diet, physical activity, and habits are not detailed in the available data. The sponsor has not provided specific inclusion or exclusion criteria for this study.

The clinical trial is designed as a **randomized**, open-label, three-period, three-treatment crossover study to evaluate the **pharmacokinetics** of alendronic acid oral formulations after a single-dose administration in healthy volunteers under fasted conditions. The trial is categorized as a Phase 3 study and is expected to commence recruitment on October 6, 2025, with an estimated completion date of November 11, 2025. The study aims to assess the pharmacokinetic profile of the drug in a controlled environment, ensuring that all participants are healthy individuals who meet the inclusion criteria and are not subject to any exclusion criteria that could affect the study's outcomes.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. This initial visit will involve a comprehensive assessment to ensure that participants are suitable for the study. Following successful screening, participants will be randomized to receive the study treatments in a crossover manner, with each treatment period separated by a washout phase to prevent carryover effects. The study will include follow-up visits after each treatment period to monitor the participants' health and collect necessary pharmacokinetic data. The end-of-study visit will conclude the trial, where final assessments will be conducted to ensure participant safety and gather any remaining data required for analysis.

The expected length of participant involvement in the study is determined by the duration of the treatment periods and the washout phases, with the entire participation period spanning several weeks. Conditions that may lead to early termination from the study include adverse events that compromise participant safety, non-compliance with study protocols, or withdrawal of consent by the participant. The study is structured to maintain scientific rigor and ensure the reliability of the data collected, contributing valuable insights into the pharmacokinetics of alendronic acid in a healthy population.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy in a Phase 3 study. The trial is scheduled to commence recruitment on October 6, 2025, with an estimated completion date of November 11, 2025. The efficacy assessment will be conducted using predefined parameters, although specific endpoints and methods for measuring efficacy are not detailed in the available data. The trial will follow a structured protocol to ensure the collection and analysis of efficacy data is consistent and reliable. The study will adhere to rigorous standards typical of Phase 3 trials, focusing on evaluating the treatment's effectiveness in a larger population. The trial's design will ensure that efficacy assessments are conducted systematically throughout the study duration, although specific timepoints and tools for these assessments are not provided in the current information.